Produção Nacional
Revisado por pares
Immunotherapy of tuberculosis withMycobacterium lepraeHsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity
2014; Taylor & Francis; Volume: 10; Issue: 5 Linguagem: Inglês
10.4161/hv.28249
ISSN2164-554X
AutoresNayara TS Doimo, Carlos R. Zárate-Bladés, Rodrigo F. Rodrigues, Cristiane Tefé‐Silva, Marcele Nogueira S. Trotte, Patricia Souza, Luana Silva Soares, Wendy Martin Rios, Elaine M. Floriano, Izaíra Tincani Brandão, Ana Paula Masson, Verônica Coelho, Simone G. Ramos, Célio Lopes Silva,
Tópico(s)vaccines and immunoinformatics approaches
ResumoDespite substantial efforts in recent years toward the development of new vaccines and drugs against tuberculosis (TB), success has remained elusive. Immunotherapy of TB with mycobacterial Hsp65 as a DNA vaccine (DNA-hsp65) results in a reduction of systemic bacterial loads and lung tissue damage, but the high homology of Hsp65 with the mammalian protein raises concern that pathological autoimmune responses may also be triggered. We searched for autoimmune responses elicited by DNA-hsp65 immunotherapy in mice chronically infected with TB by evaluating the humoral immune response and comprehensive histopathology using stereology. Cross-reactive antibodies between mycobacterial and mammalian Hsp60/65 were detected; however, no signs of pathological autoimmunity were found up to 60 days after the end of the therapy.
Referência(s)